Quantitative longitudinal interrelationships between brain metabolism and amyloid deposition during a 2-year follow-up in patients with early Alzheimer's disease
The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Purpose Similar regional anatomical distributions were reported for fibrillary amyloid deposition [measured by (11)C-Pittsburgh compound B (PIB) positron emission tomography (PET)] and brain hypometabolism [measured by (18)F-fluorodeoxyglucose (FDG) PET] in numerous Alzheimer's disease (AD) studies. However, there is a lack of longitudinal studies evaluating the interrelationships of these two different pathological markers in the same AD population. Our most recent AD study suggested that the longitudinal pattern of hypometabolism anatomically follows the pattern of amyloid deposition with temporal delay, which indicates that neuronal dysfunction may spread within the anatomical pattern of amyloid pathology. Based on this finding we now hypothesize that in early AD patients quantitative longitudinal decline in hypometabolism may be related to the amount of baseline amyloid deposition during a follow-up period of 2 years.Methods Fifteen patients with mild probable AD underwent baseline (T1) and follow-up (T2) examination after 24 ± 2.1 months with [(18)F]FDG PET, [(11)C]PIB PET, structural T1-weighted MRI and neuropsychological testing [Consortium to Establish a Registry for Alzheimer's Disease (CERAD) neuropsychological battery]. Longitudinal cognitive measures and quantitative PET measures of amyloid deposition and metabolism [standardized uptake value ratios (SUVRs)] were obtained using volume of interest (VOI)-based approaches in the frontal-lateral-retrosplenial (FLR) network and in predefined bihemispheric brain regions after partial volume effect (PVE) correction of PET data. Statistical group comparisons (SUVRs and cognitive measures) between patients and 15 well-matched elderly controls who had undergone identical imaging procedures once as well as Pearson's correlation analyses within patients were performed.Results Group comparison revealed significant cognitive decline and increased mean PIB/decreased FDG SUVRs in the FLR network as well as in several AD-typical regions in patients relative to controls. Concurrent with cognitive decline patients showed longitudinal increase in mean PIB/decrease in mean FDG SUVRs over time in the FLR network and in several AD-typical brain regions. Correlation analyses of FLR network SUVRs in patients revealed significant positive correlations between PIB T1 and delta FDG (FDG T1-T2) SUVRs, between PIB T1 and PIB T2 SUVRs, between FDG T1 and PIB T2 SUVRs as well as between FDG T1 and FDG T2 SUVRs, while significant negative correlations were found between FDG T1 and delta PIB (PIB T1-T2) SUVRs as well as between FDG T2 and delta FDG (FDG T1-T2) SUVRs. These findings were confirmed in locoregional correlation analyses, revealing significant associations in the same directions for two left hemispheric regions and nine right hemispheric regions, showing the strongest association for bilateral precuneus.Conclusion Baseline amyloid deposition in patients with mild probable AD was associated with longitudinal metabolic decline. Additionally, mildly decreased/relatively preserved baseline metabolism was associated with a longitudinal increase in amyloid deposition. The latter bidirectional associations were present in the whole AD-typical FLR network and in several highly interconnected hub regions (i.e. in the precuneus). Our longitudinal findings point to a bidirectional quantitative interrelationship of the two investigated AD pathologies, comprising an initial relative maintenance of neuronal activity in already amyloid-positive hub regions (neuronal compensation), followed by accelerated amyloid deposition, accompanied by functional neuronal decline (neuronal breakdown) along with cognitive decline.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Discordance between imaging biomarkers has been noted in sporadic AD 37–44.”
From Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer's disease: a longitudinal study (2018) · cites this paper as [44]
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · cited 1×
“Alzheimer’s disease (AD) is a progressive neurodegenerative disorder, which is characterized by extracellular accumulation of amyloid plaques and intracellular neurofibrillary tangles as well as neuronal dysfunction and loss of synapses in the course of neurodegeneration [1, 2].”
BackgroundDesikan, R. S., Ségonne, F., Fischl, B., Quinn, B. T., Dickerson, B. C., Blacker, D., Buckner, R. L., Dale, A. M., Maguire, R. P., Hyman, B. T., et al. (2006) · NeuroImage · doi:10.1016/j.neuroimage.2006.01.021 · Cited by 13,324 · cited 1×
“Accordingly, SUVRs were also obtained in single predefined locoregional grey matter VOIs (32 cortical VOIs for each hemisphere based on the Desikan atlas Freesurfer parcellation from 40 MRI scans that include young, middle-aged and elderly controls as well as patients with AD [22]: banks of superior temporal sulcus, c…”
MethodThe Brain's Default Network: Anatomy, Function, and Relevance to Disease
Buckner, R. L., Andrews‐Hanna, J. R., & Schacter, D. L. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1440.011 · Cited by 9,761
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496 · cited 1×
“The two most commonly used PET biomarkers in AD allow for noninvasive examination of fibrillary amyloid burden [C-labelled Pittsburgh compound B (PIB)] and neuronal dysfunction [F-labelled fluorodeoxyglucose (FDG)] and were shown to reveal specific anatomical patterns of reduced brain metabolism [3–7] and [C]PIB uptak…”
BackgroundAlzheimer's Disease Is a Synaptic Failure
Selkoe, D. J. (2002) · Science · doi:10.1126/science.1074069 · Cited by 4,420 · cited 1×
“From a pathophysiological point of view there is broad evidence for a direct downstream relationship between beta-amyloid and synaptic failure in AD [38].”
BackgroundGreicius, M. D., Srivastava, G., Reiss, A. L., & Menon, V. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308627101 · Cited by 3,684 · cited 1×
“However, it still remains unknown whether the reported DMN dysfunction in AD [27] is a functional consequence of beta-amyloid deposition.”
BackgroundBuckner, R. L., Snyder, A. Z., Shannon, B. J., LaRossa, G., Sachs, R., Fotenos, A. F., Sheline, Y. I., Klunk, W. E., Mathis, C. A., Morris, J. C., et al. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.2177-05.2005 · Cited by 2,140 · cited 1×
“As the regions belonging to the FLR network (including the precuneus), shown to be susceptible for amyloid pathology [20, 21], are so-called hub regions of the default mode network (DMN), one may further speculate that increased intrinsic activity in such hub regions during a lifespan could facilitate later developmen…”
BackgroundAPP Processing and Synaptic Function
Kamenetz, F., Tomita, T., Hsieh, H., Seabrook, G., Borchelt, D., Iwatsubo, T., Sisodia, S., & Malinow, R. (2003) · Neuron · doi:10.1016/s0896-6273(03)00124-7 · Cited by 1,644 · cited 1×
“Neuronal activity has been shown to increase the production and accumulation of beta-amyloid, suggesting that beta-amyloid may promote its own production via alterations in neuronal network activity [25, 26].”
Synaptic Activity Regulates Interstitial Fluid Amyloid-β Levels In Vivo
Cirrito, J. R., Yamada, K. A., Finn, M. B., Sloviter, R. S., Bales, K. R., May, P. C., Schoepp, D. D., Paul, S. M., Mennerick, S., & Holtzman, D. M. (2005) · Neuron · doi:10.1016/j.neuron.2005.10.028 · Cited by 1,265 · cited 1×
“Neuronal activity has been shown to increase the production and accumulation of beta-amyloid, suggesting that beta-amyloid may promote its own production via alterations in neuronal network activity [25, 26].”
BackgroundJack, C. R., Lowe, V. J., Weigand, S. D., Wiste, H. J., Senjem, M. L., Knopman, D. S., Shiung, M. M., Gunter, J. L., Boeve, B. F., Kemp, B. J., et al. (2009) · Brain · doi:10.1093/brain/awp062 · Cited by 1,099 · cited 2×
“However, other recent AD studies reported small but significant increases in PIB retention in AD patients over time [11, 15].”
ResultLongitudinal assessment of Aβ and cognition in aging and Alzheimer disease
Villemagne, V. L., Pike, K. E., Chételat, G., Ellis, K. A., Mulligan, R. S., Bourgeat, P., Ackermann, U., Jones, G., Szoeke, C., Salvado, O., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22248 · Cited by 833 · cited 2×
“Previous cross-sectional AD studies reported negative correlations between increased mean PIB binding and decreased FDG uptake in temporal and parietal cortical areas but not in frontal cortex [29, 30], while a longitudinal increase of PIB in AD is a well-established finding [15, 31].”
BackgroundResultAssociations between cognitive, functional, and FDG-PET measures of decline in AD and MCI
Landau, S. M., Harvey, D., Madison, C. M., Koeppe, R. A., Reiman, E. M., Foster, N. L., Weiner, M. W., & Jagust, W. J. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.07.002 · Cited by 750 · cited 1×
“In a previous longitudinal FDG PET study with a comparable follow-up period Landau and colleagues showed that metabolic decline was associated with cognitive decline as measured by the Alzheimer’s Disease Assessment Scale–cognitive subscale (ADAS-cog) [28].”
MethodEarly Aβ accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain
Ingelsson, M., Fukumoto, H., Newell, K. L., Growdon, J. H., Hedley–Whyte, E. T., Frosch, M. P., Albert, M. S., Hyman, B. T., & Irizarry, M. C. (2004) · Neurology · doi:10.1212/01.wnl.0000115115.98960.37 · Cited by 666
Two-year follow-up of amyloid deposition in patients with Alzheimer's disease
Engler, H., Forsberg, A., Almkvist, O., Blomquist, G., Larsson, E., Savitcheva, I., Wall, A., Ringheim, A., Langstrom, B., & Nordberg, A. (2006) · Brain · doi:10.1093/brain/awl178 · Cited by 617 · cited 1×
“Similarly, relatively stable PIB retention but decline in cerebral metabolism after 2 years of follow-up was shown in an earlier report from 16 AD patients [14].”
BackgroundDisruption of Functional Connectivity in Clinically Normal Older Adults Harboring Amyloid Burden
Hedden, T., Van Dijk, K. R. A., Becker, J. A., Mehta, A., Sperling, R. A., Johnson, K. A., & Buckner, R. L. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.3189-09.2009 · Cited by 598
Brain Glucose Hypometabolism and Oxidative Stress in Preclinical Alzheimer's Disease
Mosconi, L., Pupi, A., & De Leon, M. J. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1427.007 · Cited by 595 · cited 1×
“This means that besides beta-amyloid pathology there might exist additional local pathologies contributing to neuronal dysfunction (hypometabolism), such as grey/white matter atrophy, or others like inflammation, oxidative stress, myelin loss and astrocyte degradation [33–37].”
BackgroundAlexander, G. E., Chen, K., Pietrini, P., Rapoport, S. I., & Reiman, E. M. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.5.738 · Cited by 532 · cited 1×
“The two most commonly used PET biomarkers in AD allow for noninvasive examination of fibrillary amyloid burden [C-labelled Pittsburgh compound B (PIB)] and neuronal dysfunction [F-labelled fluorodeoxyglucose (FDG)] and were shown to reveal specific anatomical patterns of reduced brain metabolism [3–7] and [C]PIB uptak…”
BackgroundAmyloid, hypometabolism, and cognition in Alzheimer disease: An [11C]PIB and [18F]FDG PET study
Edison, P., Archer, H. A., Hinz, R., Hammers, A., Pavese, N., Tai, Y. F., Hotton, G., Cutler, D., Fox, N., Kennedy, A., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000244749.20056.d4 · Cited by 518
Diagnostic Criteria for Neuropathologic Assessment of Alzheimer’s Disease
Braak, H., & Braak, E. (1997) · Neurobiology of Aging · doi:10.1016/s0197-4580(97)00062-6 · Cited by 410
Drzezga, A., Becker, J. A., Van Dijk, K. R. A., Sreenivasan, A., Talukdar, T., Sullivan, C., Schultz, A. P., Sepulcre, J., Putcha, D., Greve, D., et al. (2011) · Brain · doi:10.1093/brain/awr066 · Cited by 378
Self-citationAmyloid beta from axons and dendrites reduces local spine number and plasticity
Wei, W., Nguyen, L. N., Kessels, H. W., Hagiwara, H., Sisodia, S., & Malinow, R. (2010) · Nature Neuroscience · doi:10.1038/nn.2476 · Cited by 357 · cited 1×
“A recent preclinical study confirmed direct synaptotoxic effects of beta-amyloid leading to reduced numbers of synapses [39].”
BackgroundDirect voxel-based comparison between grey matter hypometabolism and atrophy in Alzheimer's disease
Chetelat, G., Desgranges, B., Landeau, B., Mezenge, F., Poline, J. B., de la Sayette, V., Viader, F., Eustache, F., & Baron, J.-C. (2007) · Brain · doi:10.1093/brain/awm288 · Cited by 339 · cited 1×
“This means that besides beta-amyloid pathology there might exist additional local pathologies contributing to neuronal dysfunction (hypometabolism), such as grey/white matter atrophy, or others like inflammation, oxidative stress, myelin loss and astrocyte degradation [33–37].”
BackgroundGouw, A. A., Seewann, A., Vrenken, H., van der Flier, W. M., Rozemuller, J. M., Barkhof, F., Scheltens, P., & Geurts, J. J. G. (2008) · Brain · doi:10.1093/brain/awn265 · Cited by 281
Grimmer, T., Riemenschneider, M., Förstl, H., Henriksen, G., Klunk, W. E., Mathis, C. A., Shiga, T., Wester, H.-J., Kurz, A., & Drzezga, A. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.01.027 · Cited by 278 · cited 1×
“The two most commonly used PET biomarkers in AD allow for noninvasive examination of fibrillary amyloid burden [C-labelled Pittsburgh compound B (PIB)] and neuronal dysfunction [F-labelled fluorodeoxyglucose (FDG)] and were shown to reveal specific anatomical patterns of reduced brain metabolism [3–7] and [C]PIB uptak…”
BackgroundSelf-citationNg, S., Villemagne, V. L., Berlangieri, S., Lee, S.-T., Cherk, M., Gong, S. J., Ackermann, U., Saunder, T., Tochon-Danguy, H., Jones, G., et al. (2007) · Journal of Nuclear Medicine · doi:10.2967/jnumed.106.037762 · Cited by 258 · cited 1×
“Previous cross-sectional AD studies reported negative correlations between increased mean PIB binding and decreased FDG uptake in temporal and parietal cortical areas but not in frontal cortex [29, 30], while a longitudinal increase of PIB in AD is a well-established finding [15, 31].”
BackgroundEffect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease
Drzezga, A., Grimmer, T., Henriksen, G., Mühlau, M., Perneczky, R., Miederer, I., Praus, C., Sorg, C., Wohlschläger, A., Riemenschneider, M., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181a2e8d0 · Cited by 248 · cited 1×
“The two most commonly used PET biomarkers in AD allow for noninvasive examination of fibrillary amyloid burden [C-labelled Pittsburgh compound B (PIB)] and neuronal dysfunction [F-labelled fluorodeoxyglucose (FDG)] and were shown to reveal specific anatomical patterns of reduced brain metabolism [3–7] and [C]PIB uptak…”
BackgroundSelf-citationCohen, A. D., Price, J. C., Weissfeld, L. A., James, J., Rosario, B. L., Bi, W., Nebes, R. D., Saxton, J. A., Snitz, B. E., Aizenstein, H. A., et al. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.3669-09.2009 · Cited by 240 · cited 3×
“Another study focussed on the relationships between cognitive status, neuronal function and beta-amyloid deposition by correlating brain metabolism and PIB retention in groups with different cognitive status (AD vs MCI vs PIB-positive controls) [16].”
BackgroundVillain, N., Fouquet, M., Baron, J.-C., Mezenge, F., Landeau, B., de La Sayette, V., Viader, F., Eustache, F., Desgranges, B., & Chetelat, G. (2010) · Brain · doi:10.1093/brain/awq203 · Cited by 237
Drzezga, A., Grimmer, T., Henriksen, G., Stangier, I., Perneczky, R., Diehl-Schmid, J., Mathis, C. A., Klunk, W. E., Price, J., & DeKosky, S. (2008) · NeuroImage · doi:10.1016/j.neuroimage.2007.09.020 · Cited by 204 · cited 1×
“, Adliswil, Switzerland) was applied, as described previously [18].”
MethodSelf-citationDynamic changes in PET amyloid and FDG imaging at different stages of Alzheimer's disease
Kadir, A., Almkvist, O., Forsberg, A., Wall, A. E., Engler, H., Långström, B., & Nordberg, A. K. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.06.015 · Cited by 170 · cited 3×
“In the same subjects, brain FDG uptake showed a subtle longitudinal decline in the MCI stage and a more pronounced decline in clinical stages of AD [13].”
BackgroundResultZiolko, S. K., Weissfeld, L. A., Klunk, W. E., Mathis, C. A., Hoge, J. A., Lopresti, B. J., DeKosky, S. T., & Price, J. C. (2006) · NeuroImage · doi:10.1016/j.neuroimage.2006.05.063 · Cited by 132 · cited 1×
“In order to control for between-subject differences in PET tracer uptake, data sets were scaled to the mean uptake value of the cerebellar grey matter, according to the standard reference tissue model [19].”
MethodFollow-up of [ 11 C]PIB uptake and brain volume in patients with Alzheimer disease and controls
Scheinin, N. M., Aalto, S., Koikkalainen, J., Lötjönen, J., Karrasch, M., Kemppainen, N., Viitanen, M., Någren, K., Helin, S., Scheinin, M., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181bacf1b · Cited by 128 · cited 1×
“Two AD studies using serial PIB PET and MRI scans showed relatively stable longitudinal PIB retention while grey matter atrophy proceeded in a 1- or 2-year follow-up period [11, 12].”
Förster, S., Grimmer, T., Miederer, I., Henriksen, G., Yousefi, B. H., Graner, P., Wester, H.-J., Förstl, H., Kurz, A., Dickerson, B. C., et al. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.04.023 · Cited by 119 · cited 4×
“5 T Magnetom Symphony (Siemens AG, Erlangen, Germany), using the same protocols/parameters and preprocessing steps as published previously [4].”
BackgroundMethodResultSelf-citationSpatial patterns of brain amyloid- burden and atrophy rate associations in mild cognitive impairment
Tosun, D., Schuff, N., Mathis, C. A., Jagust, W., Weiner, M. W., & Initiative, A. D. N. (2011) · Brain · doi:10.1093/brain/awr044 · Cited by 117
Grimmer, T., Tholen, S., Yousefi, B. H., Alexopoulos, P., Förschler, A., Förstl, H., Henriksen, G., Klunk, W. E., Mathis, C. A., Perneczky, R., et al. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.05.013 · Cited by 101 · cited 1×
“Previous cross-sectional AD studies reported negative correlations between increased mean PIB binding and decreased FDG uptake in temporal and parietal cortical areas but not in frontal cortex [29, 30], while a longitudinal increase of PIB in AD is a well-established finding [15, 31].”
BackgroundSelf-citationFunctional Representation of Olfactory Impairment in Early Alzheimer's Disease
Förster, S., Vaitl, A., Teipel, S. J., Yakushev, I., Mustafa, M., la Fougère, C., Rominger, A., Cumming, P., Bartenstein, P., Hampel, H., et al. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-091549 · Cited by 70 · cited 1×
“The two most commonly used PET biomarkers in AD allow for noninvasive examination of fibrillary amyloid burden [C-labelled Pittsburgh compound B (PIB)] and neuronal dysfunction [F-labelled fluorodeoxyglucose (FDG)] and were shown to reveal specific anatomical patterns of reduced brain metabolism [3–7] and [C]PIB uptak…”
BackgroundSelf-citationFDG-PET mapping the brain substrates of visuo-constructive processing in Alzheimer´s disease
Förster, S., Teipel, S. J., Zach, C., Rominger, A., Cumming, P. D., la Fougère, C., Yakushev, I. Y., Haslbeck, M., Hampel, H. J., Bartenstein, P., et al. (2009) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2009.09.012 · Cited by 45 · cited 1×
“The two most commonly used PET biomarkers in AD allow for noninvasive examination of fibrillary amyloid burden [C-labelled Pittsburgh compound B (PIB)] and neuronal dysfunction [F-labelled fluorodeoxyglucose (FDG)] and were shown to reveal specific anatomical patterns of reduced brain metabolism [3–7] and [C]PIB uptak…”
BackgroundSelf-citationFörster, S., Buschert, V. C., Buchholz, H., Teipel, S. J., Friese, U., Zach, C., la Fougère, C., Rominger, A., Drzezga, A. E., Hampel, H. J., et al. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-100996 · Cited by 37 · cited 1×
“A longitudinal study in MCI patients had observed such a relationship between cognitive status and metabolic decline [3], while another study found a close relationship between metabolic decline and continuous decline in cognition in the manifest stage rather than in the preclinical MCI stage of AD [13].”
ResultSelf-citationAbnormal white matter independent of hippocampal atrophy in amnestic type mild cognitive impairment
Bai, F., Zhang, Z., Watson, D. R., Yu, H., Shi, Y., & Yuan, Y. (2009) · Neuroscience Letters · doi:10.1016/j.neulet.2009.07.009 · Cited by 19 · cited 1×
“This means that besides beta-amyloid pathology there might exist additional local pathologies contributing to neuronal dysfunction (hypometabolism), such as grey/white matter atrophy, or others like inflammation, oxidative stress, myelin loss and astrocyte degradation [33–37].”
Background
Cited by
Gordon, B. A., Blazey, T. M., Su, Y., Hari-Raj, A., Dincer, A., Flores, S., Christensen, J., McDade, E., Wang, G., Xiong, C., et al. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30028-0 · Cited by 602
Self-citationResistance vs resilience to Alzheimer disease: Clarifying terminology for preclinical studies
Arenaza-Urquijo, E. M., & Vemuri, P. (2018) · Neurology · doi:10.1212/wnl.0000000000005303 · Cited by 369
Gupta, Y., Lama, R. K., Kwon, G.-R., & Initiative, A. D. N. (2019) · Frontiers in Computational Neuroscience · doi:10.3389/fncom.2019.00072 · Cited by 155
Regional brain hypometabolism is unrelated to regional amyloid plaque burden
Altmann, A., Ng, B., Landau, S. M., Jagust, W. J., & Greicius, M. D. (2015) · Brain · doi:10.1093/brain/awv278 · Cited by 115
“One criticism that our interpretation is likely to encounter is that there may be a time lag between regional amyloid plaque deposition and a given region later becoming dysfunctional (Forster et al. , 2012).”
Riederer, I., Bohn, K. P., Preibisch, C., Wiedemann, E., Zimmer, C., Alexopoulos, P., & Förster, S. (2018) · Radiology · doi:10.1148/radiol.2018170575 · Cited by 106
Self-citation
Metadata
- Authors
- Förster, S., Yousefi, B. H., Wester, H.-J., Klupp, E., Rominger, A., Förstl, H., Kurz, A., Grimmer, T., & Drzezga, A.
- Affiliations
- TUM Klinikum (DE)
- Ludwig-Maximilians-Universität München (DE)
- Technical University of Munich (DE)
- Corresponding author
- Förster, Stefan
- ORCID
- Venue
- European Journal of Nuclear Medicine and Molecular Imaging
- Published
- 2012-08-28
- Volume
- 39
- Issue
- 12
- Pages
- 1927-1936
- ISSN
- 1619-7070 (ISSN-L)
- 1619-7089
- OpenAlex
- W2019395409
- Cited by
- 45
- References
- 40
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 2 · 2023: 2 · 2022: 2 · 2021: 2 · 2020: 2 · 2019: 3 · 2018: 3 · 2017: 5 · 2016: 3 · 2015: 9 · 2014: 5 · 2013: 4
- FWCI
- 4.10
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- European Journal of Nuclear Medicine and Molecular Imaging (publishedVersion)
- PubMed (publishedVersion)
- mediaTUM (Technical University of Munich) (submittedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Keywords
- Alzheimer's disease, amyloid deposition, brain hypometabolism, Pittsburgh compound B PET, FDG-PET, cognitive decline, partial volume correction, standardized uptake value ratio, early Alzheimer's disease, brain atrophy
- MeSH terms
- Aged, Alzheimer Disease, Amyloid, Aniline Compounds, Brain, Female, Follow-Up Studies, Humans, Longitudinal Studies, Magnetic Resonance Imaging, Male, Middle Aged, Thiazoles, Case-Control Studies, Radiopharmaceuticals, Fluorodeoxyglucose F18, Positron-Emission Tomography
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.